Exacerbations Among Patients Receiving Breztri (EROS Study)

Completed

Conditions studied: Pulmonary Disease, Chronic Obstructive, Retrospective Studies

In brief

EROS was a retrospective analysis of people with COPD using the MORE2 Registry®. Inclusion required ≥1 severe, ≥2 moderate, or ≥1 moderate exacerbation while on other maintenance treatment. Primary outcomes were the rate of COPD exacerbations and healthcare costs for those that received BGF promptly. The effect of each 30-day delay in initiation of BGF was estimated using a multivariable negative binomial regression model.

Key facts

Study ID
NCT06514144
Run by
AstraZeneca
People needed
2409
Starts
2022-10-01
Expected to finish
2023-03-07
Last updated by the study team
2024-12-13

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.